Achilles Therapeutics PLC Alpha and Beta Analysis

ACHLDelisted Stock  USD 1.48  0.00  0.00%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Achilles Therapeutics PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Achilles Therapeutics over a specified time horizon. Remember, high Achilles Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Achilles Therapeutics' market risk premium analysis include:
Beta
(0.88)
Alpha
0.66
Risk
3.09
Sharpe Ratio
0.15
Expected Return
0.48
Please note that although Achilles Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Achilles Therapeutics did 0.66  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Achilles Therapeutics PLC stock's relative risk over its benchmark. Achilles Therapeutics PLC has a beta of 0.88  . As the market becomes more bullish, returns on owning Achilles Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Achilles Therapeutics is expected to outperform it slightly. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Achilles Therapeutics Backtesting, Achilles Therapeutics Valuation, Achilles Therapeutics Correlation, Achilles Therapeutics Hype Analysis, Achilles Therapeutics Volatility, Achilles Therapeutics History and analyze Achilles Therapeutics Performance.

Achilles Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Achilles Therapeutics market risk premium is the additional return an investor will receive from holding Achilles Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Achilles Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Achilles Therapeutics' performance over market.
α0.66   Î²-0.88

Achilles Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Achilles Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Achilles Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Achilles Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Achilles Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Achilles Therapeutics shares will generate the highest return on investment. By understating and applying Achilles Therapeutics stock market price indicators, traders can identify Achilles Therapeutics position entry and exit signals to maximize returns.

Achilles Therapeutics Return and Market Media

The median price of Achilles Therapeutics for the period between Thu, Dec 26, 2024 and Wed, Mar 26, 2025 is 1.19 with a coefficient of variation of 12.42. The daily time series for the period is distributed with a sample standard deviation of 0.16, arithmetic mean of 1.25, and mean deviation of 0.14. The Stock received some media coverage during the period.
 Price Growth (%)  
JavaScript chart by amCharts 3.21.151232025FebMar 010203040
JavaScript chart by amCharts 3.21.15Achilles Therapeutics PLC Achilles Therapeutics PLC Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Achilles Therapeutics Announces 12M AstraZeneca Deal, Plans Job Cuts
12/24/2024
2
12 Health Care Stocks Moving In Tuesdays Pre-Market Session - Benzinga
02/04/2025
3
Achilles Therapeutics stock hits 52-week high at 1.41 - Investing.com
03/13/2025

About Achilles Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Achilles or other delisted stocks. Alpha measures the amount that position in Achilles Therapeutics PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Achilles Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Achilles Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Achilles Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Achilles Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Achilles Therapeutics. Please utilize our Beneish M Score to check the likelihood of Achilles Therapeutics' management manipulating its earnings.
5th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Achilles Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Consideration for investing in Achilles Stock

If you are still planning to invest in Achilles Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achilles Therapeutics' history and understand the potential risks before investing.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
CEOs Directory
Screen CEOs from public companies around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk